BHVN
Biohaven Ltd.Company Information
- Company Name
- Biohaven Ltd.
- CIK
- CIK0001935979
- Category
- Large accelerated filer
- Ticker: Exchange
- BHVN: NYSE
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- BHVN
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-11-17
- Last sale
- 2023-12-29
- Shares purchased (TTM)
- 4,507,099
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 140,113,495
- Shares outstanding
- 150,636,620
- Ownership
- 93.01%
Earnings Market Reaction
- Filing date
- 2026-08-10
- Price on filing date
- —
- 1-month reaction
- 7.91%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 238 | 273 | 230 | 185 | 166 | 98 | 99 | 84 | 239 | 183 | 248 | 112 | ||||||
| Marketable Securities Current | 30 | 75 | 89 | 75 | 239 | 224 | 387 | 294 | 198 | 101 | 133 | 129 | ||||||
| Prepaid Expense Current | 27 | 35 | 47 | 55 | 61 | 56 | 49 | 55 | 60 | 46 | 35 | 34 | ||||||
| Other Assets Current | 2 | 3 | 2 | 8 | 8 | 4 | 3 | 1 | 7 | 11 | 12 | 23 | ||||||
| Income Taxes Receivable | - | - | - | - | - | - | 3 | 5 | 8 | 8 | 13 | 13 | ||||||
| Restricted Cash Current | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Assets Current | 297 | 386 | 368 | 324 | 475 | 383 | 538 | 441 | 511 | 349 | 442 | 311 | ||||||
| Property Plant And Equipment Net | 15 | 15 | 16 | 18 | 19 | 18 | 17 | 18 | 19 | 17 | 17 | 18 | ||||||
| Intangible Assets Net Excluding Goodwill | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | ||||||
| Goodwill | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Other Assets Noncurrent | 39 | 46 | 47 | 48 | 37 | 39 | 40 | 32 | 33 | 33 | 34 | 35 | ||||||
| Assets | 371 | 466 | 451 | 409 | 550 | 459 | 615 | 511 | 583 | 419 | 513 | 383 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 12 | 10 | 12 | 17 | 20 | 19 | 18 | 20 | 17 | 36 | 16 | 10 | ||||||
| Accrued Liabilities Current | 51 | 42 | 104 | 74 | 79 | 57 | 51 | 64 | 58 | 50 | 40 | 53 | ||||||
| Liabilities Current | 63 | 52 | 116 | 113 | 124 | 164 | 154 | 152 | 156 | 87 | 55 | 62 | ||||||
| Operating Lease Liability Noncurrent | 33 | 38 | 40 | 40 | 30 | 31 | 33 | 25 | 26 | 27 | 28 | 28 | ||||||
| Derivative Liabilities Noncurrent | - | - | - | - | - | - | - | 12 | 12 | - | - | - | ||||||
| Long Term Notes Payable | 259 | 242 | 239 | 268 | 257 | - | 0 | - | - | - | - | - | ||||||
| Other Liabilities Noncurrent | 3 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 4 | 3 | 2 | 2 | ||||||
| Liabilities | 359 | 337 | 399 | 426 | 416 | 199 | 192 | 195 | 199 | 117 | 85 | 93 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 2,139 | 2,133 | 1,934 | 1,744 | 1,743 | 1,689 | 1,657 | 1,382 | 1,299 | 911 | 888 | 619 | ||||||
| Additional Paid In Capital | 220 | 203 | 194 | 178 | 157 | 137 | 112 | 93 | 84 | 69 | 40 | 26 | ||||||
| Retained Earnings Accumulated Deficit | -2,352 | -2,215 | -2,085 | -1,939 | -1,766 | -1,567 | -1,346 | -1,159 | -999 | -679 | -499 | -355 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 5 | 8 | 8 | 0 | -0 | 0 | 0 | 0 | -0 | -0 | -0 | 0 | ||||||
| Stockholders Equity | 12 | 130 | 52 | -17 | 135 | 259 | 423 | 316 | 384 | 301 | 428 | 290 | ||||||
| Liabilities And Stockholders Equity | 371 | 466 | 451 | 409 | 550 | 459 | 615 | 511 | 583 | 419 | 513 | 383 | ||||||
| Preferred Stock No Par Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock No Par Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Shares Authorized | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | ||||||
| Common Stock Shares Issued | 151 | 151 | 133 | 106 | 106 | 102 | 101 | 95 | 92 | 82 | 81 | 68 | ||||||
| Shares Outstanding | 151 | 151 | 133 | 106 | 106 | 102 | 101 | 95 | 92 | 82 | 81 | 68 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialBiohaven Ltd. (BHVN) — SEC Financial Statements & Analysis
Biohaven Ltd. (BHVN) is a pharmaceutical preparations company, incorporated in D8. Biohaven Ltd. trades on NYSE as: BHVN. Biohaven Ltd. (BHVN)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-10. Based on that filing, Biohaven Ltd. carries a market cap of $2.24B, a P/E ratio of -3.82x, a P/B ratio of 183.40x, an enterprise value of $2.26B, and an EV/EBITDA multiple of -4.06x. On profitability, it posts a Return on Equity (ROE) of -799.46%, a Return on Assets (ROA) of -127.41%, and a Return on Invested Capital (ROIC) of -447.27%. Per share, it reports EPS of $-3.90, diluted EPS of $-3.90, free cash flow per share of $-3.40, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of -23.49% year-over-year and EPS growth of -48.00% year-over-year. On the balance sheet, it maintains a current ratio of 4.73x, a quick ratio of 4.30x, working capital of $233.90M, a debt-to-equity ratio of 29.33x, a debt ratio of 0.97, free cash flow of $-511.87M (TTM), and net debt of $18.85M. Figures sourced from SEC EDGAR.
- Market Cap
- $2.24B
- P/E TTM
- -3.82x
- EPS TTM
- $-3.90
- P/B TTM
- 183.40x
- ROE TTM
- -799.46%
- ROA TTM
- -127.41%
- Debt To Equity
- 29.33x
- Free Cash Flow TTM
- $-511.87M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Biohaven Ltd. in?
Biohaven Ltd. (BHVN) operates in the Pharmaceutical Preparations industry.
What exchange does BHVN trade on?
Biohaven Ltd. (BHVN) trades on the NYSE.
Where is Biohaven Ltd. incorporated?
Biohaven Ltd. is incorporated in Virgin Islands, British.
When was Biohaven Ltd. (BHVN)'s most recent SEC filing?
Biohaven Ltd. (BHVN)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-10.
What is BHVN's market cap?
Biohaven Ltd. (BHVN) has a market capitalization of $2.24B as of 2026-06-30.
What is BHVN's EPS (earnings per share)?
Biohaven Ltd. (BHVN)'s trailing twelve month EPS is $-3.90 as of 2026-06-30.
What is BHVN's ROE (return on equity)?
Biohaven Ltd. (BHVN)'s trailing twelve month Return on Equity (ROE) is -799.46% as of 2026-06-30.
What is BHVN's ROA (return on assets)?
Biohaven Ltd. (BHVN)'s trailing twelve month Return on Assets (ROA) is -127.41% as of 2026-06-30.
What is BHVN's ROIC (return on invested capital)?
Biohaven Ltd. (BHVN)'s trailing twelve month Return on Invested Capital (ROIC) is -447.27% as of 2026-06-30.
What is BHVN's EV/EBITDA?
Biohaven Ltd. (BHVN)'s trailing twelve month EV/EBITDA is -4.06x as of 2026-06-30.